Analyst firms · Morgan Stanley · INCY

Morgan Stanley INCY price target and rating history

Incyte Corp. (INCY) · Health Care

Morgan Stanley rates Incyte Corp. (INCY) Equal-Weight with a $119 price target, as of its latest action on Oct 20, 2026. It has published 3 rating actions on INCY since September 2021, including 0 upgrades and 0 downgrades. Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Morgan Stanley's target matches it.

Current rating
Equal-Weight
Price target
$119
Median target, all firms
$119
Actions on INCY
3

Morgan Stanley price target on INCY

$119$98$7620222023202420252026
Morgan Stanley price target on INCY, each point a stated target, September 2021 to October 2026.

Every Morgan Stanley rating on INCY

How other firms rate INCY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$144Oct 30, 2026
Morgan StanleyEqual-Weight$119Oct 20, 2026
Canaccord GenuityBuy$152Aug 20, 2026
BMO Capital MarketsMarket Perform$94Jun 22, 2026
BernsteinMkt Perform$99May 22, 2026
JefferiesHold$94Mar 16, 2026
H.C. WainwrightBuy$135Feb 5, 2026
Wells FargoEqual Weight$107Jan 20, 2026
MizuhoOutperform$121Dec 8, 2025

Questions about Morgan Stanley and INCY

What is Morgan Stanley's price target for INCY?
Morgan Stanley's latest stated price target for Incyte Corp. (INCY) is $119, from its action on Oct 20, 2026.
What is Morgan Stanley's rating on INCY?
Morgan Stanley rates INCY Equal-Weight, a neutral rating, as of Oct 20, 2026.
When did Morgan Stanley last change its view on INCY?
On Oct 20, 2026, Morgan Stanley resumes coverage at Equal-Weight, price target $119.
How does Morgan Stanley's INCY target compare with other analysts?
Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Morgan Stanley's target matches it.

More INCY rating histories

All Morgan Stanley ratingsINCY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.